Overview
EN ISO 10993-5:2009/A11:2025 is a CEN amendment to the international standard for the biological evaluation of medical devices - Part 5: Tests for in vitro cytotoxicity. Published March 2025, Amendment A11 updates the European foreword and Annex ZA to clarify the relationship between in vitro cytotoxicity testing and the General Safety and Performance Requirements of Regulation (EU) 2017/745 (MDR). The amendment supports harmonized evaluation of material- and substance‑related cytotoxic effects on mammalian cells and establishes its role in regulatory conformity assessments when cited in the Official Journal of the EU.
Key Topics
- Scope and purpose: Provides a voluntary, standardized means to determine the in vitro cytotoxic response of mammalian cells to medical device materials, substances, residues and degradation products.
- Test selection and strategy: Guidance on selecting appropriate in vitro cytotoxicity approaches consistent with risk management and device intended use (e.g., extract testing, contact methods) - as part of a biological evaluation process.
- Sample preparation and controls: Reference to standardized sample handling and use of suitable positive/negative controls (linked normatively to ISO 10993‑12 for sample preparation).
- Interpretation and reporting: Framework for evaluating and documenting cytotoxicity findings to support risk assessment and clinical safety claims.
- Relationship to regulation: Annex ZA maps clauses to relevant MDR General Safety and Performance Requirements and explains the limits of coverage (e.g., ADME aspects, flammability and some design/manufacture requirements are not covered).
- Limitations: The standard only addresses in vitro cytotoxicity and does not replace other biocompatibility tests or requirements for design, manufacture, nanomaterials special considerations, or in vivo evaluations where needed.
Applications
Who uses EN ISO 10993-5:2009/A11:2025 and why:
- Medical device manufacturers - to plan and document cytotoxicity testing as part of biological evaluation and technical files for regulatory submissions.
- Regulatory affairs & notified bodies - to assess conformity with MDR General Safety and Performance Requirements when the standard is cited.
- Testing laboratories and CROs - to implement harmonized in vitro cytotoxicity methods and reporting practices.
- Quality, risk and clinical evaluation teams - to integrate cytotoxicity data into overall risk management and post‑market surveillance.
Practical use cases include preclinical safety screening of new materials, evaluation of residual contaminants, and supporting evidence for biocompatibility dossiers.
Related Standards
Keywords: EN ISO 10993-5:2009/A11:2025, in vitro cytotoxicity, biological evaluation, medical devices, ISO 10993, cytotoxicity testing, biocompatibility testing, MDR 2017/745.
